Molecular dispersions of drospirenone

• US 20050220825A1
• Filed: 03/10/2005
• Published: 10/06/2005
• Est. Priority Date: 03/10/2004
• Status: Abandoned Application

• Current Assignee: Bayer Schering Pharma AG (Bayer AG)
• Original Assignee: Bayer Schering Pharma AG (Bayer AG)
• Inventors: Funke, Adrian, Wagner, Torsten
• Application Number:
  US11/076,034
• Publication Number:
  US 20050220825A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence

Abstract

Described are pharmaceutical compositions comprising at least one steroidal drug such as a progestin (e.g. drospirenone, progesterone, eplerenone, etonogestrel) and/or an estrogen (estradiol and esters thereof) in molecularly dispersed form. The composition comprises a steroidal drug, preferably drospirenone, which is present in the composition in a non-particulate form. Preferably, the drug is present in a dissolved state in the excipient. The molecularly dispersed drug will be released very fast as dissolution takes place instantly when the dosage unit has disintegrated. Also described are methods for preparing the pharmaceutical compositions and methods of using the compositions.

Claims

1. A composition comprising Drospirenone molecularly dispersed in at least one pharmaceutically acceptable carrier.

2. The composition according to claim 1 in the form of a liquid or a semi-solid, wherein at least one of the pharmaceutically acceptable carriers is selected from the group consisting of glycerol, propylene glycol, ethylendiglycolmonoethylether, polyols, citric acid esters, monoglycerides, diglycerides, vegetable oils, vegetable fats, partial synthetic triglycerides, synthetic triglycerides, mixtures of glycerol fatty acid esters, fatty alcohols, fatty alcohol ethers, fatty acids, fatty acid esters, waxes, paraffin and mixtures thereof.

3. The composition according to claim 2, further comprising at least one emulgator.

4. The composition according to claim 1, wherein the at least one pharmaceutically acceptable carrier is selected from the group consisting of medium chain triglycerides, ricinus oil, Glycerolmonocaprylat, caprylaic/capric glycerides, Polyoxyethylene-35-glycerol-triricinoleate, Polyoxyethylene-40-Glycerol-hydroxystearate, polyethylene glycol 400, diethylene glycol monoethyl ether, triethyl citrate and mixtures thereof.

5. The composition according to claim 4, wherein the at least one pharmaceutically acceptable carrier is selected from the group consisting of glycerol and polyethylene glycol 400, a mixture of Glycerolmonocaprylat and polyethylene glycol 400, a mixture of ricinus oil and tributyl citrate, a mixture of ricinus oil and polyethylene glycol 400, a mixture of caprylaic/capric glycerides and polyethylene glycol 400, a mixture of caprylaic/capric glycerides and polyethylene glycol 400 and ethanol.

6. The composition according to claim 1, in a form of a micro-emulsion pre-concentrate.

7. The composition according to claim 1, in the form of a solid, wherein at least one of the pharmaceutically acceptable carriers is a solid at room temperature and/or has a melting point in the range of 40-80°

C and is selected from the group consisting of polyethylene glycol 6000 vegetable oils, vegetable fats, partial synthetic triglycerides, synthetic triglycerides, mixtures of glycerol fatty acid esters, mixtures of mono-, di and triglycerides, polyoxyethylene glycerol fatty acid esters, fatty acids, fatty acid esters, waxes, paraffin, and mixtures thereof.

8. The composition according to claim 1, wherein the pharmaceutically acceptable carrier is a polymer, preferably a hydrophilic polymer.

9. The composition according to claim 8, wherein the hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidone;

polyvinyl acetate;

polyvinyl alcohol;

polyvinyl alcohol phthalate;

polyethylene glycol;

polyethylene oxide;

gelatine;

carbomer;

methacrylic acid copolymer;

ammonio methacrylate copolymer;

cellulose, carboxymethyl-cellulose;

methyl cellulose;

hydroxy ethyl cellulose;

hydroxypropyl methylcellulose, hydroxypropyl-cellulose;

cellulose acetate phthalate; and

hydroxypropyl methylcellulose phthalate;

crospovidone;

sodium starch glycolate;

croscarmellose; and

copolymers thereof, and mixtures thereof.

10. The composition according to claim 1, wherein the composition further comprises an estrogen.

11. A process for providing Drospirenone molecularly dispersed in a pharmaceutically acceptable carrier comprising the steps of

a) providing Drospirenone and one or more carrier(s);

and

b) dissolving the Drospirenone completely in the one or more carrier(s); and

c) optionally, drying the mixture obtained in step b).

12. The process according to claim 11, wherein the step of dissolving Drospirenone is performed by means selected from the group consisting of heating, ultrasonic treatment, vigorously mixing, stirring and melt extruding.

13. The process according to claim 11, wherein the carrier is in the form of a liquid or a semi-solid, wherein at least one of the pharmaceutically acceptable carriers is selected from the group consisting of glycerol, propylene glycol, ethylendiglycolmonoethylether, polyols, citric acid esters, monoglycerides, diglycerides, vegetable oils, vegetable fats, partial synthetic triglycerides, synthetic triglycerides, mixtures of glycerol fatty acid esters, fatty alcohols, fatty alcohol ethers, fatty acids, fatty acid esters, waxes, paraffin and mixtures thereof.

14. The process according to claim 11, wherein the carrier further comprises at least one emulgator.

15. The process according to claim 11, wherein the at least one pharmaceutically acceptable carrier is selected from the group consisting of medium chain triglycerides, ricinus oil, Glycerolmonocaprylat, caprylaic/capric glycerides, Polyoxyethylene-35-glycerol-triricinoleate, Polyoxyethylene-40-Glycerol-hydroxystearate, polyethylene glycol 400, diethylene glycol monoethyl ether, triethyl citrate and mixtures thereof.

16. The process according to claim 11, wherein the at least one pharmaceutically acceptable carrier is selected from the group consisting of glycerol and polyethylene glycol 400, a mixture of Glycerolmonocaprylat and polyethylene glycol 400, a mixture of ricinus oil and tributyl citrate, a mixture of ricinus oil and polyethylene glycol 400, a mixture of caprylaic/capric glycerides and polyethylene glycol 400, a mixture of caprylaic/capric glycerides and polyethylene glycol 400 and ethanol.

17. The process according to claim 11, wherein the mixture resulting from step b) or c) is in the form of a micro-emulsion pre-concentrate.

18. The process according to claim 11, wherein at least one of the pharmaceutically acceptable carriers is a solid at room temp and/or has a melting point in the range of 40-80°

C. and is selected from the group consisting of polyethylene glycol 6000 vegetable oils, vegetable fats, partial synthetic triglycerides, synthetic triglycerides, mixtures of glycerol fatty acid esters, mixtures of mono-, di and triglycerides, polyoxyethylene glycerol fatty acid esters, fatty acids, fatty acid esters, waxes, paraffin, and mixtures thereof.

19. The process according to claim 11, wherein the pharmaceutically acceptable carrier is a polymer, preferably a hydrophilic polymer.

20. The process according to claim 19, wherein the hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidone;

polyvinyl acetate;

polyvinyl alcohol;

polyvinyl alcohol phthalate;

polyethylene glycol;

polyethylene oxide;

gelatine;

carbomer;

methacrylic acid copolymer;

ammonio methacrylate copolymer;

cellulose, carboxymethyl-cellulose;

methyl cellulose;

hydroxy ethyl cellulose;

hydroxypropyl methylcellulose, hydroxypropyl-cellulose;

cellulose acetate phthalate; and

hydroxypropyl methylcellulose phthalate;

crospovidone;

sodium starch glycolate;

croscarmellose; and

copolymers thereof, and mixtures thereof.